维莫非尼联合利妥昔单抗成功治疗复发性毛细胞白血病1例  

A Successful Case of Vemurafenib and Rituximab for Relapsed Hairy Cell Leukemia

作　　者：秋昱翀 李美姿 张路[1] 李剑[1] QIU Yuchong;LI Meizi;ZHANG Lu;LI Jian(Department of Hematology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;Department of Gastroenterology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;4+4 Medical Doctor Program,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医院血液科,北京100730 [2]中国医学科学院北京协和医院消化内科,北京100730 [3]中国医学科学院北京协和医学院临床医学专业试点班,北京100730

出　　处：《罕见病研究》2025年第1期106-111,共6页Journal of Rare Diseases

基　　金：首都临床诊疗技术研究及转化应用项目(Z211100002921016);中央高水平医院临床科研业务费(2022-PUMCH-A-021)。

摘　　要：毛细胞白血病(HCL)是一种在临床上较为罕见的血液系统恶性肿瘤。本文报道了1例复发性HCL患者的诊疗过程。患者为51岁女性,于2013年6月确诊为HCL,并接受克拉屈滨单药化疗,化疗后评估疗效为部分缓解。2023年11月出现胸闷、憋气,超声示右侧胸腔积液。2024年2月复查示HCL复发,予维莫非尼联合利妥昔单抗治疗,迅速达到完全缓解并不伴微小残留病。本病例可为复发性HCL的治疗提供参考。Hairy cell leukemia(HCL)is a rare malignant hematological tumor.This article presents the diagnosis and treatment of a patient with recurrent HCL.This patient,a 51-year-old female,was diagnosed with HCL in June 2013 and subsequently received monotherapy with cladribine.Post-treatment evaluation indicated a partial remission.In November 2023,she experienced chest tightness and shortness of breath with ultrasound revealing a right-sided pleural effusion.A follow-up examination in February 2024 confirmed the relapse of HCL.She was then treated with a combination of vemurafenib and rituximab,which resulted in a rapid complete remission without minimal residual disease.This case provides valuable insights into the management of recurrent HCL.

关 键 词：毛细胞白血病 复发 BRAF抑制剂 利妥昔单抗 

分 类 号：R733.7[医药卫生—肿瘤]